EORTC-NCI-AACR--20th symposium molecular targets and cancer therapeutics: mechanisms of targeting for cancer treatment.
Fakorede
Adebola
A
Thomas Reuters, London, UK. adebola.fakorede@thomsonreuters.com
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D003580:Cytochromes / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics / Q000378:metabolism; D051880:Receptors, Notch / Q000187:drug effects; D000097869:Polo-Like Kinase 1
D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D003580:Cytochromes; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D019859:Proto-Oncogene Proteins c-met; D051880:Receptors, Notch; D000097869:Polo-Like Kinase 1